Alere Inc (ALR)

50.35
NYSE : Health Care
Prev Close 50.35
Day Low/High 50.09 / 50.51
52 Wk Low/High 34.41 / 50.64
Avg Volume 1.32M
Exchange NYSE
Shares Outstanding 87.58M
Market Cap 4.41B
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Short Interest Expands By 17% For ALR

Short Interest Expands By 17% For ALR

The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 1,032,989 share increase in total short interest for Alere Inc , to 7,151,868, an increase of 16.88% since 08/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

This week's bullish and bearish reversal patterns.

Weekly Roundup

Strong earnings and guidance lift markets. We drop a couple of names from the portfolio.

Immunalysis Receives FDA Clearance For SEFRIA™ Fentanyl Urine Drug Screening Test

Immunalysis Receives FDA Clearance For SEFRIA™ Fentanyl Urine Drug Screening Test

First-ever 510(k)-cleared fentanyl enzyme immunoassay brings high-performance qualitative screening to a wide range of healthcare settings

Weekly Roundup

Earnings help boost markets as D.C. isn't counted on for much of anything. Portfolio action (it was a busy week) includes a new position and a downgrade.

Abbott Labs Reports Strong Quarter

Stock remains a strong performer in our portfolio.

Abbott CEO: Another Alere-Related Divestiture Coming Soon

Abbott CEO: Another Alere-Related Divestiture Coming Soon

Abbott CEO Miles White said on an earnings call the company will make one more asset sale as part of efforts to gain regulatory approval for the Abbott-Alere deal.

Alere, St. Jude Deals in Focus as Abbott Releases Q2 Earnings

Alere, St. Jude Deals in Focus as Abbott Releases Q2 Earnings

Abbott will report second-quarter numbers on Thursday as it completes the Alere deal. $ABT $ALR

Alere Launches Alere ICup® Rx Drug Screen For Detecting Commonly Misused And Abused Prescription Drugs

Alere Launches Alere ICup® Rx Drug Screen For Detecting Commonly Misused And Abused Prescription Drugs

Rapid Urine Test Facilitates Real-time Monitoring of Use, Misuse and Abuse of Clinically Relevant Prescription Pain and Addiction Therapies

Quidel Diversifies With Alere's Triage Assets

Quidel Diversifies With Alere's Triage Assets

The Triage assets are being divested in order to secure antitrust approvals for Abbott Laboratories' purchase of Alere.

Earnings Previews: 7 Names to Report This Week

What we'll be looking for from ABT, NUE, DHR, KEY, SNA, GE and SLB.

Short Interest In Alere Moves 17.3% Higher

Short Interest In Alere Moves 17.3% Higher

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 496,718 share increase in total short interest for Alere Inc. , to 3,374,652, an increase of 17.26% since 06/15/2017.

Weekly Roundup

Jobs report and Fed minutes highlight a short week. In the portfolio, we add one name and downgrade another.

Alere Shareholders Vote to Approve Amended Merger with Abbott

Alere Shareholders Vote to Approve Amended Merger with Abbott

The final vote results will be filed on a Form 8-K with the Securities and Exchange Commission.

Weekly Roundup

Tech rotation, oil and Fed rate hike keep markets on even (make that flat) keel. Several portfolio positions get beefed up.

Abbott Is on Track to Meet Integration Objectives

In turn, this will increase the company's profit margins.

Weekly Roundup

After a busy Thursday, markets look forward to economic data and the Fed meeting next week. In the portfolio, we dropped a tech stock and added a healthcare name.

Xilinx, Alere, Xerox, Huntsman: 'Mad Money' Lightning Round

Xilinx, Alere, Xerox, Huntsman: 'Mad Money' Lightning Round

Jim Cramer likes Xilinx and Abbott Labs, but he's bearish on Xerox and Huntsman.

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

TheStreet Quant Rating: C (Hold)